Further development of colovac, a multi-antigen multi-peptide vaccine, for colon cancer prevention
Ended Awarded Last action
- Contract number
- 75N91019F00131
- Awardee
-
University Of Alabama At Birmingham UEI YND4PLMC9AN7
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,044,896
Award facts
- Opportunity
- Contract value 100% obligated
- $1,044,896.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Birmingham, AL 35294, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$7,872 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,052,768 |
About this award
The University of Alabama at Birmingham was awarded a $1,044,896 firm fixed price delivery order against the PREVENT Preclinical Drug Development Program master IDIQ contract by the National Cancer Institute, part of the National Institutes of Health within the Department of Health and Human Services. The delivery order is for further development of Colovac, a multi-antigen multi-peptide vaccine for colon cancer prevention, in support of the PREVENT Efficacy Pool program. The University of Washington Office of Sponsored Programs Division was identified as a major subcontractor to assist in performance at the prime contractor's location in Birmingham, Alabama from September 2019 through December 2022.
Quick answers
Who was awarded contract 75N91019F00131?
75N91019F00131 was awarded to University Of Alabama At Birmingham by National Cancer Institute (National Institutes of Health) on September 15, 2019.
How much is contract 75N91019F00131 worth?
The government has obligated $1,044,896 on 75N91019F00131.
Is contract 75N91019F00131 an order under another contract?
Yes. 75N91019F00131 is a delivery order under 75N91019D00019, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91019F00131 competed?
The extent of competition for 75N91019F00131 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award